ERCC1 and non-small cell lung carcinoma: Median OS for patients treated with chemotherapy in the real world ranged from 7.3 to 16 months (Fig 2).[28, 30, 34, 35, 37, 38, 44, 51] Median OS did not appear to be substantially affected by patients’ age group,[35] or by presence of the excision repair cross-complementation group 1 (ERCC1) biomarker,[44] which has previously been used to help select therapy in non-small-cell lung cancer.